Abstract
A critical appraisal and clinical application of Meltzer HY, Cucchiaro J, Silva R, Ogasa M, Phillips D, Xu J, Kalali AH, Scheizer E, Pikalov A, Loebel A. Lurasidone in the treatment of schizophrenia: a randomized, double-blind, placebo- and olanzapine-controlled study. Am J Psychiatry. 2011 Sep;168(9):957-67. doi: https://doi.org/10.1176/appi.ajp.2011.10060907.
DOI
10.22237/crp/1536278400
Recommended Citation
ORAL HY. Lurasidone is not associated with risk of QTc prolongation. Clin. Res. Prac. 2018 Sep 14;4(2):eP1679. doi: 10.22237/crp/1536278400
COinS
